Baxalta announced the launch of Adynovate (antihemophilic factor [recombinant], PEGylated), after receiving approval from the Food and Drug Administration (FDA) for on-demand treatment and control of bleeding episodes, and routine prophylaxis to reduce the frequency of bleeding episodes in patients with hemophilia A aged ≥12 years.
All articles by Stephen Duffy
Latest News Your top articles for ThursdayFor More Personalized News
Haymarket Medical NetworkTop Picks
Continuing Medical Education (CME/CE) Courses